Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Vivani Medical Inc. (VANI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: VANI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 2.38% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.93M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 88451 | Beta 3.5 | 52 Weeks Range 1.00 - 2.22 | Updated Date 04/1/2025 |
52 Weeks Range 1.00 - 2.22 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date 2025-03-24 | When Before Market | Estimate -0.11 | Actual -0.11 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.74% | Return on Equity (TTM) -105.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 69963796 | Price to Sales(TTM) - |
Enterprise Value 69963796 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.93 | Shares Outstanding 66600800 | Shares Floating 31303164 |
Shares Outstanding 66600800 | Shares Floating 31303164 | ||
Percent Insiders 48.98 | Percent Institutions 8.41 |
Analyst Ratings
Rating 4 | Target Price 5.5 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vivani Medical Inc.
Company Overview
History and Background
Vivani Medical Inc. (formerly Second Sight Medical Products) focuses on developing miniaturized, long-term implantable drug delivery systems. Founded originally to develop retinal prosthetics, the company pivoted to drug delivery systems. It has undergone significant restructuring and strategic shifts in recent years.
Core Business Areas
- Drug Delivery Systems: Vivani Medical develops miniaturized, long-term drug delivery systems. Their primary focus is on the development of their lead product, Nepro, an investigational miniature drug implant designed for the long-term continuous delivery of exenatide for the treatment of type 2 diabetes.
Leadership and Structure
The leadership team includes Michael Redmond as CEO. The company structure is typical of a small, publicly traded biotech, with functional departments supporting research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- Nepro: Nepro is an investigational miniature drug implant designed for the long-term continuous delivery of exenatide for the treatment of type 2 diabetes. It's currently in clinical development. Market share data is not yet applicable as the product isn't approved. Competitors include companies developing other long-acting diabetes treatments, such as Novo Nordisk (NVO), Eli Lilly (LLY), and Medtronic (MDT), focusing on insulin pumps and continuous glucose monitoring systems. There are also many oral medications competing with injectable medications.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the diabetes market, is highly competitive and characterized by continuous innovation in drug delivery systems and therapeutic options.
Positioning
Vivani Medical aims to carve a niche in the diabetes treatment market with its miniaturized, long-term drug delivery system. It's competing with established players with larger resources and a wider range of products.
Total Addressable Market (TAM)
The global diabetes market is estimated to be worth hundreds of billions of dollars. Vivani Medical aims to capture a segment of this market through a novel drug delivery system, but their portion of the TAM is heavily dependent on successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel drug delivery technology
- Potential for improved patient compliance
- Focus on a large and growing market (diabetes)
Weaknesses
- Limited financial resources
- Reliance on a single product candidate
- Clinical and regulatory risks
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion to other therapeutic areas
- Positive clinical trial results
Threats
- Competition from established diabetes treatments
- Unfavorable clinical trial outcomes
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- NVO
- LLY
- MDT
Competitive Landscape
Vivani Medical faces significant competition from larger, more established companies in the diabetes market. Its success hinges on the differentiated features of its drug delivery system. VANI current market share in the diabetes market is negligible, reflecting its development stage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historically the company growth has been poor with a focus on retinal implants that were not commercially successful.
Future Projections: Future growth depends on successful clinical trials of Nepro and subsequent commercialization. Analyst estimates will vary based on their assessment of these probabilities.
Recent Initiatives: The most recent initiative is the development and clinical testing of Nepro for the treatment of type 2 diabetes.
Summary
Vivani Medical is a development-stage biotech company with a novel drug delivery system for diabetes. Its success depends on the outcome of clinical trials and securing regulatory approval. The company has limited financial resources and faces stiff competition from established players. Failure of clinical trials or inability to raise capital would be detrimental.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice. Please do your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vivani Medical Inc.
Exchange NASDAQ | Headquaters Alameda, CA, United States | ||
IPO Launch date 2014-11-19 | Co-Founder, CEO & Director Dr. Adam Mendelsohn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://www.vivani.com |
Full time employees 36 | Website https://www.vivani.com | ||
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.